| Literature DB >> 26473822 |
Damião Pergentino de Sousa1, Palloma de Almeida Soares Hocayen2, Luciana Nalone Andrade3, Roberto Andreatini4.
Abstract
The clinical efficacy of standardized essential oils (such as Lavender officinalis), in treating anxiety disorders strongly suggests that these natural products are an important candidate source for new anxiolytic drugs. A systematic review of essential oils, their bioactive constituents, and anxiolytic-like activity is conducted. The essential oil with the best profile is Lavendula angustifolia, which has already been tested in controlled clinical trials with positive results. Citrus aurantium using different routes of administration also showed significant effects in several animal models, and was corroborated by different research groups. Other promising essential oils are Citrus sinensis and bergamot oil, which showed certain clinical anxiolytic actions; along with Achillea wilhemsii, Alpinia zerumbet, Citrus aurantium, and Spiranthera odoratissima, which, like Lavendula angustifolia, appear to exert anxiolytic-like effects without GABA/benzodiazepine activity, thus differing in their mechanisms of action from the benzodiazepines. The anxiolytic activity of 25 compounds commonly found in essential oils is also discussed.Entities:
Keywords: anxiety; anxiolytic; elevated plus maze; essential oil; lavender; natural products; relaxant; sedative; terpene; tranquillizer
Mesh:
Substances:
Year: 2015 PMID: 26473822 PMCID: PMC6332383 DOI: 10.3390/molecules201018620
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Summary of studies with essential oils in animal models of anxiety (only essential oils with at least one positive result are included).
| Essential Oils | Administration | Specie | Anxiety Model | Observed Effect | Motor Activity | Mechanism of Action | Observation | Reference | |
|---|---|---|---|---|---|---|---|---|---|
| Inhalation (acute) | Mouse | Elevated plus-maze | Anxiolytic-like | Not evaluated | 10-min session | [ | |||
| i.p. | Rat | Elevated plus-maze | Anxiolytic-like? | Decrease | Female only | [ | |||
| Oral (acute) | Mice | Light/Dark | Anxiolytic-like? | Decrease | Toxicity? | [ | |||
| i.p. (acute) | Rat | Elevated plus-maze | Anxiolytic-like | Decrease? | Not mediated by BDZ | DR+ | [ | ||
| i.p. (acute) | Mouse | Elevated plus-maze | No effect | Decrease | DR+ | [ | |||
| Inhalation (acute) | Mouse | Elevated plus-maze | Anxiolytic-like | No change | Decrease 5-HTP and fluoxetine induced jumping (5-HT action) | Motor activity evaluated trough rearing | [ | ||
| Inhalation (3 days) | Mouse | Elevated plus-maze | Anxiolytic-like | No change | DR− | [ | |||
| Inhalation (5–150 min) | Mouse | Elevated plus-maze | Anxiolytic-like | No change | Anxiolytic-like effect is dependent of duration of inhalation (30–120 min) | [ | |||
| Oral (acute) | Mouse | Elevated plus-maze | Anxiolytic-like | No change | Inverted U curve | [ | |||
| Oral (acute) | Rat | Social Interaction | Putative Anxiolytic-like | Increase | Inverted U curve | [ | |||
| Oral (acute) | Rat | Elevated plus-maze | No effect | No change | Positive effect when compared to caffeine only | [ | |||
| Oral (repeated) | Rat | Elevated plus-maze | Anxiolytic-like | No change | [ | ||||
| Inhaled (acute) | Mouse | Elevated plus-maze | Anxiolytic-like | Not evaluated | 10-min session | [ | |||
| Inhaled (repeated) | Rat | Elevated plus-maze | Reversed | Not evaluated | Associated with IL-6 and Ccl2 cytokines reductions | DR− | [ | ||
| Oral | Mouse | Elevated plus-maze | Anxiolytic-like | No change | DR+ | [ | |||
| Oral | Mouse | Marble-burying | Anxiolytic-like | No change | DR+ | [ | |||
| Inhalation | rats | Social interaction | Anxiolytic-like | No change | DR+ | [ | |||
| Oral | Mouse | Light/Dark | Anxiolytic-like | No change | 5-HT1A-receptors | DR+ | [ | ||
| i.p. (acute) | Mouse | Elevated plus-maze | Anxiolytic-like | Not evaluated | DR+ | [ | |||
| i.p. (acute) | Mouse | Elevated plus-maze | Anxiolytic-like | Not evaluated | GABA partial agonist? | Reduced diazepam anxiolytic-effect | [ | ||
| Rat | Elevated plus-maze | Anxiolytic-like? | Increase? | inverted U-shaped curve | [ | ||||
| Inhalation | Mouse | Elevated plus-maze | Anxiolytic-like | No change | DR+ | [ | |||
| Inhalation (repeated) | Rats | Elevated plus-maze | Decrease anxiogenic-like effect of icv | Not evaluated | Not tested in naive rats | [ | |||
| Lemon | Inhalation (continuous for 1 week) | Rat (male/female) | Elevated plus-maze | Anxiogenic-like | No change | DR− | [ | ||
| Inhalation | Mouse | Elevated plus-maze | Anxiolytic-like? | Decrease | 5-HTergic | DR− | [ | ||
| Oral (acute) | Mouse | Elevated plus-maze | Anxiolytic-like? | Decrease | inverted U-shaped curve DR+ | [ | |||
| Oral | Mouse | Marble-burying Light/Dark | Anxiolytic-like Anxiolytic-like | No change | inverted U-shaped curve | [ | |||
| Oral | Mouse | Marble-burying | Anxiolytic-like | No change | DR+ | [ | |||
| Inhalation | Rat | Light/Dark | Anxiolytic-like | No change | [ | ||||
| Oral (acute) | Rat | Elevated plus-maze | Anxiolytic-like | No change | DR+ | [ | |||
| Oral | Mouse | Open Field | Anxiolytic-like | No change | DR+ | [ | |||
| Oral | Mouse | Marble-burying | Anxiolytic-like | No change | GABA-A /BDZ | DR+ | [ | ||
| i.p. (acute) | Mice (male/Female) | Elevated plus-maze | Anxiolytic-like * | Not evaluated | Inconsistency in data showed in figure and text | [ | |||
| Oral (acute) | Mouse | Elevated plus-maze | Anxiolytic-like | No change | DR+ | [ | |||
| Oral | Mouse | Elevated plus-maze | Anxiolytic-like | No change | inverted U-shaped curve | [ | |||
| i.p. | Mouse | Geller conflict | Anxiolytic-like | No change | DR+ | [ | |||
| Inhalation | Mouse | Elevated plus-maze | No effect | DR− | [ | ||||
| Inhalation (24 h) | Gerbil (male/female) | Elevated plus-maze | Anxiolytic-like | Anxiolytic in male and female | [ | ||||
| Inhalation | rat | Open Field | Anxiolytic-like | Not evaluated | Increase immobility (sedation) | [ | |||
| Inhalation | rat | Open Field | Anxiolytic-like | No change | Reduction in c-fos increases with open field exposition | [ | |||
| Inhalation | Sheep | Reaction to stress (isolation) | Mixed results | change | Nervous sheep: anxiogenic; calm sheep: | [ | |||
| Inhalation | Mouse | Elevated plus-maze | Anxiolytic-like | No change | Anxiolytic-like effect correlated with | [ | |||
| Inhalation | Mouse | Elevated plus-maze | Anxiolytic-like | Similar effect in stressed and non-stressed mice | [ | ||||
| Inhalation | Mouse | Elevated plus-maze | Anxiolytic-like | No change | Serotonergic system (5-HT1A) | Neutral odor control | [ | ||
| Inhalation | Mouse | Marble-burying | Anxiolytic-like | No change | Similar effects in anosmic and normal mice | [ | |||
| Inhalation | Mouse | Elevated plus-maze | Anxiolytic-like | Increase hippocampal 5-HT | Similar effects in anosmic and normal mice | [ | |||
| i.p. (repeated) | rat | Elevated plus-maze | Anxiolytic-like | Mixed results | Some results could be influenced by motor activity changes | [ | |||
| Oral (repeated) | Mouse | Elevated plus-maze | Anxiolytic-like | No change | Non selective inhibition of voltage operated calcium channels | DR+ | [ | ||
| i.p. | Mouse | Elevated-plus-maze | Anxiolytic-like | No change | DR+ | [ | |||
| i.p. (acute) | Rat | Elevated T-maze | Anxiolytic-like | No change | DR+ | [ | |||
| Oral (7 days) | Mouse | Elevated plus-maze | Anxiolytic-like? | Decrease | DR+ | [ | |||
| Inhalation (acute) | Mouse | Light/Dark | Anxiolytic-like? | Decrease | inverted U-shaped curve | [ | |||
| Inhalation (repeated) | Rat | elevated plus-maze | Decrease anxiogenic-like effect of icv beta-amyloid (1–42) | No change | Not tested in naive rats | [ | |||
| Inhalation (repeated) | Rat | elevated plus-maze | Decrease anxiogenic-like effect of icv beta-amyloid (1–42) | No change | Not tested in naive rats | [ | |||
| Inhalation (acute) | Mouse | Light/Dark | Anxiolytic-like? | Mixed results | DR+ | [ | |||
| Oral (14 days) | Mouse | Elevated plus-maze | Anxiolytic-like | No change | Effect in stressed mice | [ | |||
| Rat | Elevated plus-maze | Anxiolytic-like? | Increase | Female (estrous phase not specified) | [ | ||||
| i.p. | Mouse | Geller conflict | Anxiolytic-like | No change | DR+ | [ | |||
| Inhaled | Rat | Elevated plus-maze | Anxiolytic-like | Not evaluated | DR+ | [ | |||
| Inhalation (acute) | Mouse | Elevated plus-maze | No effect | No change | Ethanol as control | [ | |||
| Prolonged Inhalation (24 h) | Gerbil | Elevated plus-maze | No effect | Mixed | DR− | [ | |||
| Inhalation (acute) | Mouse | Elevated plus-maze | Anxiolytic-like in stressed mice | Not evaluated | No effect in non-stressed mice | [ | |||
| Oral (acute) | Mouse | Elevated plus-maze | Anxiolytic-like | No change | 5-HTergic | DR+ | [ | ||
| Oral (3 days) | Rat | Elevated plus-maze | Anxiolytic-like | No change | DR+ | [ | |||
| Elevated plus-maze | Anxiolytic-like | Decrease | 10 min session | [ |
Anxiolytic-like?—sedation/motor activity impairment could be a confounding variable; Toxicity?—Putative toxic effect; DR (dose/concentration-response design)—Plus (+) where at least two doses/concentrations tested; Minus (−) where only one dose/concentration tested; * Statistical significant difference cited in the text but not showed in the graphic.
Constituents isolated from essential oils with anxiolytic-like effect.
| Compound | Experimental Protocol | Anxiolytic-Like Effect and/or Mechanism | Animal Tested | Reference |
|---|---|---|---|---|
| Elevated plus-maze test | Increased exploration of the open arms | Mice | [ | |
| Elevated plus-maze test | Decreases in open-arm exploration | Rats | [ | |
| Elevated plus-maze test | Increased open arm exploration in the elevated plus maze | Mice | [ | |
| Elevated plus-maze test | Increased open arm exploration | Mice | [ | |
| Elevated plus-maze test | No effect was observed | Mice | [ | |
| Elevated plus-maze test | Increased % time spent and % entries in the open arms | Mice | [ | |
| Elevated plus-maze test | Increased mouse motor activity | Mice | [ | |
| ( | Elevated-T maze test | Reduced avoidance latency without any effect in escape time | Rats | [ |
| Geller conflict test | Increased punished behavior at dose that did not change unpunished behavior | Mice | [ | |
| Vogel conflict tests | Increased punished licking | |||
| Elevated plus-maze test | Increased time spent and % entries in the open arms | Mice | [ | |
| Elevated plus-maze test | Increased number of entries and time of permanence in the open arms | Mice | [ | |
| Light/dark test | Increased time spent in the light side without effect on the number of crossing | Mice | [ | |
| Elevated plus-maze test | Increased number of entries and time spent in the open arms | Mice | [ | |
| ( | Elevated plus-maze test | Increase in time spent and in the number of entries in the open arms | Mice | [ |
| (+)- | Marble burying test | Reduction in number of buried marbles | Mice | [ |
| Light/dark test | Increased time spent in the light side and increased social interaction | Mice | [ | |
| Light/dark test | Increased number of crossings and time spent in the light side | Mice | [ | |
| Elevated plus-maze test | Increase in open arm exploration | Rats | [ | |
| Elevated plus-maze test | Increased social interaction and decreased number of marbles buried | Mice | [ | |
| Elevated plus-maze test | Increased mouse motor activity | Mice | [ | |
| Brief mechanical restraint | Reduced struggle latency and increased struggle bouts, which would be indicative of fear reduction | Quail | [ | |
| Elevated plus-maze test | Increase in the percentile ratio of open arm to total arm entries and reduction in the time spent in the closed arms | Rats | [ |